Jilin ao Dong shares the "biological artificial liver"

Kuanzhiyong Jilin ao Dong (000623).　　SZ) announced today that it will invest 2 million U.S. dollars in the world's first to engage in biological artificial liver business of the United States Life Treatment company. The U.S. Life Treatment company is currently developing the world's first artificial liver with human stem cells: an in vitro liver accessory device, the bulletin said. The bioartificial liver can metabolize toxins like normal human liver organs and can synthesize proteins. This bioartificial liver is used to provide important metabolic and survival support for patients with severe liver failure. According to the introduction, the American Life Treatment Company has successfully completed 6 stages of clinical trials in China completed the final stage of clinical trials. Submitted a listing application to the China Food and Drug Administration in September 2007.　　The final stage clinical trial of the bioartificial Liver project in the United States and Europe is also under way in order to obtain permission and listing for us biological agents. According to the two sides signed April 2 letter of Intent, Jilin AO East stake in the United States Life Treatment company will be divided into two steps. The first step is to invest 2 million of dollars in initial investment, which will account for 5%~6% of the American Life Treatment company. If the Bioartificial liver project is approved by the China Drug Administration or the FDA, Jilin Ao Dong will invest 25 million U.S. dollars in the second stage, becoming the largest shareholder of the life Treatment company. If the biological artificial liver project is not approved by the Chinese Drug Administration or the FDA within 6 months from the date of the agreement, the cooperation between the two parties will be negotiated separately.　　At present, life Treatment company registered capital of 35 million U.S. dollars, the largest shareholder share only 16.2%. From the perspective of the agreement, Jilin AO east of the agreement also need to obtain the approval of the Department of Commerce in Jilin Province. A senior investment manager at an investment agency in Shenzhen said: "The investment in Jilin Ao Dong is essentially a venture capital in the field of biomedical medicine." From the Bulletin of Jilin AO East, the biological artificial liver project has a major doubt, need to be listed companies for further explanation. Since September 2007, China's Drug Administration has not approved the application of bio-artificial liver products, the listing of the product is there any substantial obstacles? "Jilin AO East yesterday closed at 34.7 Yuan, up 2.66% from the previous session."